Optimal treatment for Philadelphia‑negative acute lymphoblastic leukemia in first remission in the era of high‑intensity chemotherapy /// Shinichi Kako, Fumihiko Hayakawa, Kiyotoshi Imai, Junji Tanaka, Shuichi Mizuta, Satoshi Nishiwaki, Heiwa Kanamori, Junichi Mukae, Yukiyasu Ozawa, Tadakazu Kondo, Takahiro Fukuda, Tatsuo Ichinohe, Shuichi Ota, Yoshinori Tanaka, Tohru Murayama, Shingo Kurahashi, Toru Sakura, Noriko Usui, Shigeki Ohtake, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Yoshiko Atsuta /// International Journal of Hematology. DOI:10.1007/s12185-021-03198-4
Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission /// Kako S, Hayakawa F, Miyamura K, Tanaka J, Imai K, Kanda J, Morishima S, Uchida N, Doki N, Ikegame K, Ozawa Y, Takada S, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Ichinohe T, Fukuda T, Atsuta Y, Kanda Y. /// Transplant Cell Ther. 2021: S2666-6367: 01405-6. DOI:10.1016/j.jtct.2021.11.021
Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia /// Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y, Ohtake S, Kiyoi H, Miyazaki Y, Nishikawa H, Takahashi N. /// Cancers (Basel). 2021; 13: 5904. DOI:10.3390/cancers13235904
Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. /// Takeshi Saito,Yoshihiro Hatta,Fumihiko Hayakawa,Tsutomu Takahashi,Maki Hagihara,Hiroatsu Iida,Koichiro Minauchi,Etsuko Yamazaki,Isamu Sugiura,Tohru Murayama,Toru Sakura,Naoki Mori,Kiyotoshi Imai,Yuichi Yahagi,Yoshiko Atsuta,Akiko Moriya Saito,Akihiro Hirakawa,Hitoshi Kiyoi,Itaru Matsumura,Yasushi Miyazaki&Japan Adult Leukemia Study Group. /// Int J Hematol. 2021;113(3):395-403. DOI: 10.1007/s12185-020-03032-3
2021年～2030年の論文
【論文タイトル /// 全著者名 /// 掲載誌】
Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia /// Isamu Sugiura, Noriko Doki, Tomoko Hata, Ryuko Cho, Toshiro Ito, Youko Suehiro, Masatsugu Tanaka, Shinichi Kako, Mitsuhiro Matsuda, Hisayuki Yokoyama, Yuichi Ishikawa, Yasuhiro Taniguchi, Maki Hagihara, Yukiyasu Ozawa, Yasunori Ueda, Daiki Hirano, Toru Sakura, Masaaki Tsuji, Tsuyoshi Kamae, Hiroyuki Fujita, Nobuhiro Hiramoto, Masahiro Onoda, Shin Fujisawa, Yoshihiro Hatta, Nobuaki Dobashi, Satoshi Nishiwaki, Yoshiko Atsuta, Yukio Kobayashi, Fumihiko Hayakawa, Shigeki Ohtake, Tomoki Naoe, and Yasushi Miyazaki, on behalf of the Japan Adult Leukemia Study Group. /// Blood Advances (2022) 6 (2):624-636; DOI:10.1182/bloodadvances.2021004607
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. /// Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. /// Blood. 2022; 139: 1850-1862. DOI:10.1182/blood.2021011921
Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. /// Dai YT, Zhang F, Fang H, Li JF, Lu G, Jiang L, Chen B, Mao DD, Liu YF, Wang J, Peng LJ, Feng C, Chen HF, Mu JX, Zhang QL, Wang H, Ariffin H, Moy TA, Wang JH, Lou YJ, Chen SN, Wang Q, Liu H, Shan Z, Matsumura I, Miyazaki Y, Yasuda T, Dou LP, Yan XJ, Yan JS, Yeoh AE, Wu DP, Kiyoi H, Hayakawa F, Jin J, Wang SY, Sun XJ, Mi JQ, Chen Z, Huang JY, Chen SJ. /// Proc Natl Acad Sci U S A. 2022;119: e2120787119. DOI:10.1073/pnas.2120787119
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. /// Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. /// Int J Hematol. 2022; 116: 228-238. DOI:10.1007/s12185-022-03347-3
Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene. /// Koya Odaira,Takahiko Yasuda,Kentaro Okada,Takuya Shimooka,Yukino Kojima,Mina Noura,Shogo Tamura,Shingo Kurahashi,Eisuke Iwamoto,Masashi Sanada,Itaru Matsumura,Yasushi Miyazaki,Tetsuhito Kojima,Hitoshi Kiyoi,Shinobu Tsuzuki,Fumihiko Hayakawa. /// Cancer Sci. 2022 Nov 7; DOI:10.1111/cas.15641
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. /// Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. /// Blood. 2022; 139: 1850-1862. DOI:10.1182/blood.2021011921
Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. /// Dai YT, Zhang F, Fang H, Li JF, Lu G, Jiang L, Chen B, Mao DD, Liu YF, Wang J, Peng LJ, Feng C, Chen HF, Mu JX, Zhang QL, Wang H, Ariffin H, Moy TA, Wang JH, Lou YJ, Chen SN, Wang Q, Liu H, Shan Z, Matsumura I, Miyazaki Y, Yasuda T, Dou LP, Yan XJ, Yan JS, Yeoh AE, Wu DP, Kiyoi H, Hayakawa F, Jin J, Wang SY, Sun XJ, Mi JQ, Chen Z, Huang JY, Chen SJ. /// Proc Natl Acad Sci U S A. 2022;119: e2120787119. DOI:10.1073/pnas.2120787119
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. /// Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. /// Int J Hematol. 2022; 116: 228-238. DOI:10.1007/s12185-022-03347-3
Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene. /// Koya Odaira,Takahiko Yasuda,Kentaro Okada,Takuya Shimooka,Yukino Kojima,Mina Noura,Shogo Tamura,Shingo Kurahashi,Eisuke Iwamoto,Masashi Sanada,Itaru Matsumura,Yasushi Miyazaki,Tetsuhito Kojima,Hitoshi Kiyoi,Shinobu Tsuzuki,Fumihiko Hayakawa. /// Cancer Sci. 2022 Nov 7; DOI:10.1111/cas.15641
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. /// Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. /// Lancet Haematol.2023; 10: e419-e432. DOI:10.1016/S2352-3026(23)00072-8
High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. /// Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y. /// Hemasphere. 2023; 7: e899. DOI:10.1097/HS9.0000000000000899
High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. /// Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y. /// Hemasphere. 2023; 7: e899. DOI:10.1097/HS9.0000000000000899
Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT. /// Nakagawa N, Ishiyama K, Usuki K, Takada S, Tomikawa T, Handa H, Katsuoka Y, Hirano D, Sezaki N, Sumi M, Fujisawa S, Taniguchi Y, Mugitani A, Yoshimura T, Ohtsuka E, Takase K, Suehiro Y, Ota S, Kajiguchi T, Maeda T, Yamamoto M, Ohtake S, Katsumi A, Kiyoi H, Matsumura I, Miyazaki Y. /// Ann Hematol. 2024 Jan;103(1):307-320. DOI:10.1007/s00277-023-05527-5
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). /// Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Kiyoi H, Miyazaki Y. /// Int J Hematol. 2024 Jan;119(1):24-38. DOI:10.1007/s12185-023-03677-w
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). /// Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H. /// Int J Hematol. 2024; 119: 130-145. DOI:10.1007/s12185-023-03686-9
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. /// Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group. /// Am J Hematol. 2024 99(5):806-815. DOI:10.1002/ajh.27237
Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. /// Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, Noriyoshi Iriyama, Katsumichi Fujimaki, Kazuhiko Kakihana, Yoji Ogasawara, Takaaki Ono, Masaya Okada, Tetsuzo Tauchi, Toshihiro Miyamoto, Kazunori Ohnishi, Emiko Sakaida, Shin Fujisawa, Yukio Kobayashi, Norio Asou, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki for the Japan Adult Leukemia Study Group /// Blood Adv. 2024 Jul 5:bloodadvances.2024012655. DOI:10.1182/bloodadvances.2024012655
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). /// Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Kiyoi H, Miyazaki Y. /// Int J Hematol. 2024 Jan;119(1):24-38. DOI:10.1007/s12185-023-03677-w
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). /// Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H. /// Int J Hematol. 2024; 119: 130-145. DOI:10.1007/s12185-023-03686-9
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. /// Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group. /// Am J Hematol. 2024 99(5):806-815. DOI:10.1002/ajh.27237
Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. /// Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, Noriyoshi Iriyama, Katsumichi Fujimaki, Kazuhiko Kakihana, Yoji Ogasawara, Takaaki Ono, Masaya Okada, Tetsuzo Tauchi, Toshihiro Miyamoto, Kazunori Ohnishi, Emiko Sakaida, Shin Fujisawa, Yukio Kobayashi, Norio Asou, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki for the Japan Adult Leukemia Study Group /// Blood Adv. 2024 Jul 5:bloodadvances.2024012655. DOI:10.1182/bloodadvances.2024012655
